Drug Approval | August 16, 2023
Eugia Pharma receives USFDA Approval for Icatibant Injection
This is the 166th ANDA out of Eugia Pharma Speciality Group facilities
This is the 166th ANDA out of Eugia Pharma Speciality Group facilities
API, PFI, and Finished dosages contribute 30%, 15%, and 55% of revenue from operations respectively for Q1FY24
The product is being launched in August 2023
Aiming to establish a state-of-the-art healthcare facility in India that integrates the latest technologies, exceptional patient comfort, and optimal clinical outcomes
The primary purpose of this collaboration is to bring the optimized protein into the Indian market
Medica Superspecialty Hospital becomes the first private hospital in Eastern India to collaborate with UNICEF for breastfeeding workshop
Zydus' Indomethacin suppositories also been granted 180-day CGT exclusivity to market this product.
The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.
Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy
The approved product has an estimated market size of around US$ 210 million for the twelve months ending May 2023
Subscribe To Our Newsletter & Stay Updated
